Literature DB >> 17103261

Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?

Andrea Muratore1, Daria Zorzi, Hedayat Bouzari, Marco Amisano, Paolo Massucco, Elisa Sperti, Lorenzo Capussotti.   

Abstract

BACKGROUND: About 20% of patients with colorectal cancer have synchronous un-resectable liver metastases. Resection of colorectal cancer in patients with moderate-severe symptoms is mandatory before starting chemotherapy. Surgical treatment of asymptomatic colorectal cancers is still a matter of discussion.
METHODS: From January 2000 to December 2004, we prospectively collected data on 35 consecutive patients who were treated straightaway by chemotherapy without primary tumor resection. All patients underwent FOLFOX6 as first-line chemotherapy. The aim of the study was to evaluate the rate of surgical complications related to un-resected colorectal tumor.
RESULTS: The mean interval between diagnosis and start of chemotherapy was 23.1 days (95% CI: 17.3-28.8). Fifteen of the 35 patients (42.9%) were down-staged to surgery; the mean interval between chemotherapy start and colon-rectum cancer resection was 6.5 months (95% CI: 5.5-7.5). None of them developed complications related to the primary tumor during chemotherapy. Of the other 20 patients who did not undergo any curative surgery, 16 received a second line chemotherapy and 10 a third line: six patients are alive and without intestinal symptoms (mean follow up 22.5 months, 95% CI: 11.2-33.9). Only one patient (2.8%) developed clinical signs of intestinal occlusion 5.6 months from the start of chemotherapy and required urgent colostomy.
CONCLUSIONS: The rate of complications related to the non-resected colorectal tumor is very low using oxaliplatin as first line chemotherapy. Non-operative management of asymptomatic colorectal cancers with un-resectable liver metastases is a safe approach.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17103261     DOI: 10.1245/s10434-006-9146-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  50 in total

1.  Feasibility of the liver-first approach for patients with initially unresectable and not optimally resectable synchronous colorectal liver metastases.

Authors:  Masayuki Okuno; Etsuro Hatano; Yosuke Kasai; Takahiro Nishio; Satoru Seo; Kojiro Taura; Kentaro Yasuchika; Takashi Nitta; Akira Mori; Hideaki Okajima; Toshimi Kaido; Suguru Hasegawa; Shigemi Matsumoto; Yoshiharu Sakai; Shinji Uemoto
Journal:  Surg Today       Date:  2015-08-28       Impact factor: 2.549

Review 2.  Systematic review of prognostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases.

Authors:  Andrew P Stillwell; Yik-Hong Ho; Craig Veitch
Journal:  World J Surg       Date:  2011-03       Impact factor: 3.352

3.  Stage IV colorectal cancers: an analysis of factors predicting outcome and survival in 728 cases.

Authors:  Min-Hoe Chew; Jin-Yao Teo; Tousif Kabir; Poh-Koon Koh; Kong-Weng Eu; Choong-Leong Tang
Journal:  J Gastrointest Surg       Date:  2011-10-19       Impact factor: 3.452

Review 4.  Molecular Pathways: Targeting the Microenvironment of Liver Metastases.

Authors:  Simon Milette; Jason K Sicklick; Andrew M Lowy; Pnina Brodt
Journal:  Clin Cancer Res       Date:  2017-06-14       Impact factor: 12.531

Review 5.  Role of cetuximab in first-line treatment of metastatic colorectal cancer.

Authors:  Miguel Jhonatan Sotelo; Beatriz García-Paredes; Carlos Aguado; Javier Sastre; Eduardo Díaz-Rubio
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 6.  Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.

Authors:  Qing-Yang Feng; Ye Wei; Jing-Wen Chen; Wen-Ju Chang; Le-Chi Ye; De-Xiang Zhu; Jian-Min Xu
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

7.  Survival after non-resection of colorectal cancer: the argument for including non-operatives in consultant outcome reporting in the UK.

Authors:  M Abdel-Halim; H Wu; M Poustie; A Beveridge; N Scott; P J Mitchell
Journal:  Ann R Coll Surg Engl       Date:  2018-10-24       Impact factor: 1.891

Review 8.  Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review.

Authors:  Louis de Mestier; Gilles Manceau; Cindy Neuzillet; Jean Baptiste Bachet; Jean Philippe Spano; Reza Kianmanesh; Jean Christophe Vaillant; Olivier Bouché; Laurent Hannoun; Mehdi Karoui
Journal:  World J Gastrointest Oncol       Date:  2014-06-15

9.  Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone.

Authors:  A P Stillwell; P G Buettner; Y H Ho
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

Review 10.  TAS-102: a novel antimetabolite for the 21st century.

Authors:  Nataliya Uboha; Howard S Hochster
Journal:  Future Oncol       Date:  2015-11-30       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.